CCHFV Gc Specific Neutra™ Antibody Products

Are you struggling to overcome challenges in antiviral drug development, such as prolonged timelines, inconsistent neutralization assays, or limited tools for CCHFV research? Creative Biolabs' CCHVA Gc specific Neutra™ antibody products leverage proprietary antigen design and recombinant antibody engineering to streamline high-affinity antibody discovery, enabling rapid development of therapies against Crimean-Congo hemorrhagic fever virus (CCHFV).

Introduction to CCHFV Gc

CCHFV membrane fusion glycoprotein Gc (CCHFV Gc) is a virulence factor essential for viral entry into host cells. As a class III viral fusion protein, it mediates pH-dependent membrane fusion within endosomes, enabling the release of the viral genome into the cytoplasm. CCHFV Gc is highly conserved across viral strains and serves as a primary target for neutralizing antibodies.

Fig.1 CCHFV virion and replication cycle.¹

• Structural Insights

CCHFV Gc adopts a multi-domain architecture characterized by a central β-sheet core, hydrophobic fusion loops, and prefusion trimeric spikes stabilized by disulfide bonds. Structural studies reveal pH-induced conformational rearrangements that expose fusion loops for host membrane interaction. Notably, the Gc ectodomain contains immunodominant epitopes, which are critical for antibody-mediated neutralization.

• Host-Pathogen Interactions

CCHFV Gc interacts with host cell receptors such as dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), facilitating viral attachment. Subsequent clathrin-mediated endocytosis triggers Gc-mediated fusion, activating pro-inflammatory pathways (e.g., NF-κB) and immune evasion mechanisms. These interactions exacerbate vascular leakage and coagulopathy, hallmarks of severe CCHFV infection.

• Associated Disease

Crimean-Congo Hemorrhagic Fever (CCHF) is a tick-borne zoonosis with a 30% fatality rate, characterized by sudden fever, hemorrhage, and multi-organ failure. Endemic in Africa, Asia, and Europe, outbreaks are increasingly reported due to climate change and expanded vector habitats. The absence of approved vaccines or specific antivirals underscores the urgency of targeting Gc for therapeutic and prophylactic interventions.

Applications of Anti-CCHFV Gc Neutralizing Antibodies

• Therapeutic Development

Neutralizing antibodies are pivotal for post-exposure therapy, reducing viral load and mortality in preclinical models. Early administration in symptomatic patients may mitigate disease progression by blocking cell-to-cell spread.

• Diagnostic Assays

High-affinity antibodies enable rapid detection of CCHFV in clinical samples via antigen-capture ELISA or lateral flow assays, crucial for outbreak containment in resource-limited settings.

• Vaccine Efficacy Evaluation

Quantifying Gc-specific neutralizing antibodies in vaccinated individuals provides correlates of immune protection, accelerating vaccine candidate screening and optimization.

• Epidemiological Surveillance

Serological profiling using Gc-targeting antibodies helps track CCHFV seroprevalence in animal reservoirs and human populations, informing public health strategies.

Our Anti-CCHFV Gc Neutralizing Antibodies

Antibodies targeting CCHFV Gc disrupt viral entry by blocking receptor binding or preventing fusion-loop insertion into host membranes. Creative Biolabs' Antibodies demonstrate exceptional specificity for conformational epitopes, validated in pseudovirus neutralization assays and live CCHFV challenge models. Engineered for high affinity (KD <1 nM) and cross-reactivity against diverse strains, these antibodies are compatible with ELISA, flow cytometry, and in vivo neutralization studies.

Creative Biolabs offers CCHFV Gc specific Neutra™ antibody products that combine cutting-edge engineering with rigorous validation to empower your antiviral programs.

Contact our team today to discuss customized solutions for your various needs.

REFERENCE

1. Zivcec, Marko, et al. "Molecular insights into Crimean-Congo hemorrhagic fever virus." Viruses 8.4 (2016): 106. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/v8040106